ArticleThe Pan African medical journal2026
Utilization of evidence-based secondary preventive therapies post-acute coronary syndrome: a heart registry cohort study in Kenya.
Article in The Pan African medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: cardiovascular disease is a growing concern in Africa, with coronary artery disease emerging as a leading cause of mortality. Despite strong evidence and international guidelines recommending secondary prevention therapy post-acute coronary syndrome (ACS)-including antiplatelet agents, statins, beta blockers, and angiotensin-converting enzyme (ACE) inhibitors-suboptimal use remains a concern, especially in low- and middle-income countries. This study aimed to quantify the use of guideline-recommended secondary prevention medications after ACS in Kenya using the data from the Kenya Heart Registry study. Methods: a cohort study was conducted using data from the Kenya Heart Registry across three hospitals in Kenya from 2019 to 2023. Adult patients (≥18 years) diagnosed with ACS (ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), or unstable angina (UA)) were included. Clinical and sociodemographic data were extracted, including pharmacotherapy at presentation and discharge. Descriptive statistics and multivariate logistic regression (odds ratio (OR) and 95% confidence intervals) were used to assess patterns and predictors of medication use at discharge. Results: a total of 247 patients were included (168 STEMI, 79 NSTEMI/UA). Majority, 77.7%, were males and 39.3% were above the age of 65 years. More than 70% of the patients were overweight or obese. Use of secondary prevention therapy was low at home but increased significantly during hospitalization and remained high at discharge. At discharge, 91.4% of STEMI and 89.9% of NSTEMI/UA patients received aspirin; 88.3% and 84.8%, respectively, received statins. The odds of receiving a beta blocker at discharge were higher among patients with diabetes (OR=2.59) and dyslipidemia (OR=2.46), while patients with hypertension had higher odds of receiving ARB (OR=5.28). Conclusion: despite better in-hospital and discharge prescribing patterns, suboptimal pre-hospital medication use and underutilization of certain agents like ticagrelor at discharge highlight gaps in care. Tailored interventions such as provider training, patient education, and strengthened transition-of-care protocols are needed to improve long-term adherence to guideline-directed medical therapy after ACS in Kenya, particularly among high-risk groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.